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Abstract
Background: The rupture of gastric varices is associated with high mortality rate. Balloon-occluded retrograde
transvenous obliteration (B-RTO), a minimally invasive procedure that was introduced in the mid-1990s, has been
widely accepted in Japan. Several reports have indicated that B-RTO yields satisfactory results; however, few reports
have discussed the recurrence of gastric varices after this therapy. The purpose of this study is to retrospectively
evaluate the technical aspects of B-RTO and the recurrence of gastric varices after treatment with this procedure.
Methods: B-RTO was performed in 47 patients with gastric varices, who were at a risk of variceal ruptures and
who may or may not have had a history of variceal bleeding. We injected a sclerosing agent into the gastric
varices for 30-60 minutes. To evaluate the therapeutic efficacy of the technique, we obtained contrast-enhanced
computed tomography (CT) scans 5 days after B-RTO. As a general rule, if the gastric varices did not appear
thrombosed, we repeated the procedure 7 days after the first procedure.
Results: B-RTO was a technical success in 37 patients. It was performed once in 26 patients, twice in 6 patients,
thrice in 2 patients, and 4 times in 3 patients. Contrast-enhanced CT scans obtained after B-RTO showed
thrombosed gastrorenal shunts in 29 patients and patent gastrorenal shunts in 8 patients. The gastric varices
recurred in 2 patients who had patent gastrorenal shunts. The overall cumulative relapse-free rate of gastric varices
was 90% at 5 years after B-RTO.
Conclusions: B-RTO is an effective treatment modality for gastric varices. Moreover, obliteration of the gastrorenal
shunt as well as the gastric varices appears to be important for the treatment of gastric varices.
Background
The rupture of gastric varices is associated with a mor-
tality rate of 25-55% because it leads to extensive
blood loss as compared to the blood loss because of
the rupture of esophageal varices [1-4]. Because of
poor liver function and rapid blood flow in patients
with gastric varices, the development of effective treat-
ment for this condition is a challenge. Gastric varices
can be treated by endoscopic injection therapy with
cyanoacrylate, but there is a risk of migration of this
compound into systemic circulation through the infer-
ior vena cava via the gastrorenal shunt [5]. Balloon-
occluded retrograde transvenous obliteration (B-RTO),
a minimally invasive procedure that was introduced in
the mid-1990s, has been widely accepted in Japan. In
the standard technique, gastric varices are thrombosed
using a sclerosing agent that is injected through a bal-
loon catheter. Several reports have indicated that B-
RTO yields satisfactory results [6-11]; however, few
reports have discussed the recurrence of gastric varices
after this therapy. The present study was conducted to
evaluate the clinical outcomes of B-RTO performed for
the treatment of gastric varices and to investigate the
recurrence of these varices.
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Methods
Patients
Between July 1999 and September 2008, 47 patients
(30 men and 17 women; age range, 45-79 years; mean
age, 61 years) who had gastric varices with gastrorenal
or gastrocaval shunts underwent B-RTO at our hospi-
tal. The main clinical characteristics of these 47
patients are presented in Table 1. The underlying liver
disease was viral hepatitis-related liver cirrhosis in 28
patients, alcoholic liver cirrhosis in 17 patients, and
other conditions in 2 patients. According to the Child-
Pugh classification system, 28 patients were categor-
ized into class A, 18 into class B, and 1 into class C.
The gastric varices were subdivided into 2 types–gas-
troesophageal varix (GOV) and isolated gastric varix
(IGV)–according to the method established by Sarin
[2,3]. GOVs extend beyond the gastroesophageal junc-
tion and are always associated with esophageal varices.
They are further subdivided into GOV-1 and GOV-2:
GOV-1 appears as a continuation of esophageal varices
and extend for 2-5 cm below the gastroesophageal
junction along the lesser curvature of the stomach, and
GOV-2 extends beyond the gastroesophageal junction
towards the fundus of the stomach. IGVs are gastric
varices that are not accompanied by esophageal
varices; they are subdivided into IGV-1 and IGV-2.
IGV-1 is located in the fundus of the stomach, and
IGV-2 is isolated ectopic varix which can be found in
all regions of the stomach. According to this classifica-
tion, GOV-1s were found in 8 patients (17%), GOV-2s
in 20 patients (43%), and IGV-1s in 19 patients (40%).
Of these, 7 patients had previously had episodes of
bleeding from gastric varices; to control the bleeding,
endoscopic injection therapy with cyanoacrylate had
been administered as an emergency procedure to 3
patients, and endoscopic variceal ligation had been
performed in another 3. However, some varices per-
sisted or bleeding recurred. Therefore, these patients
were scheduled for B-RTO. In 1 of the patients, gastric
variceal bleeding ceased during endoscopy, and B-RTO
was scheduled without any endoscopic therapy. In the
remaining 40 patients, the procedure was performed as
a prophylactic treatment. The risks of rupture, such as
progressive varices and red spots on gastric varices,
were identified by endoscopy. The attending physician
attempted to use H2 blockers to prevent gastric ulcer
or beta-blockers to reduce portal vein pressure in
some patients before the B-RTO procedure was per-
formed. The institutional review board permitted the
data collection and approved the study. Informed writ-
ten consent was obtained from all the patients, and the
research was carried out in accordance with the Hel-
sinki Declaration.
Procedure
The B-RTO procedure is illustrated in Fig. 1. Contrast-
enhanced computed tomography (CT) was performed
before the procedure in order to visualize the anatomy
of the gastric varices and confirm the presence of a gas-
trorenal shunt. An 8-French (Fr) hook-shaped sheath
(Clinical Supply, Gifu, Japan) was inserted into the left
renal vein via the right femoral vein. If the gastric
varices did not drain via a gastrorenal shunt, the gastro-
caval shunt was directly catheterized. Depending on the
size of the shunt, a 5-Fr balloon catheter (balloon dia-
meter, 11 mm; Clinical Supply, Gifu, Japan) or a 6-Fr
balloon catheter (balloon diameter, 20 mm; Clinical
Supply, Gifu, Japan) was inserted. When the size of the
shunt was extremely large, a 7-Fr balloon catheter (bal-
loon diameter, 30 mm; Nipro, Osaka, Japan) was also
used. Initially, balloon-occlusion venography was per-
formed with an inflated balloon; however, the gastric
varices did not appear opacified because the collateral
veins, such as the inferior phrenic vein or the pericardia-
cophrenic vein, were dilated. These collateral veins were
embolized using metallic coils. In case the collateral
veins were small and numerous, we used a small
amount of an ethanolamine oleate-iopamidol (EOI) mix-
ture containing 10% ethanolamine oleate (Oldamin;
Takeda Pharmaceuticals, Osaka, Japan) diluted with an
equal amount of iopamidol (Iopamiron 300; Bayer
Healthcare, Osaka, Japan). After the occlusion of the
collateral veins, balloon-occlusion venography was per-
formed again to confirm that the contrast medium had
filled the gastric varices. Even if the gastric varices were
not sufficiently filled by the contrast medium after the
Table 1 Main characteristics of the 47 patients
Sex (M/F) 30/17
Age (mean) 45 - 79 (61)
Cause of liver disease, no. (%)
Postviral 28 (60)
Alcoholic 17 (36)
Autoimmune hepatitis 1 (1)
Extra hepatic portal vein stenosis post surgery 1 (1)
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occlusion of the collateral veins, the splenic artery was
temporarily occluded by a balloon catheter in order to
reduce the inflow route from the short gastric vein or
posterior gastric vein. We injected the EOI mixture into
the shunt and gastric varices for 30-60 minutes without
prolonged occlusion with a balloon catheter. During the
injection, we monitored the position of the balloon
catheter by using fluoroscopy to avoid catheter dislodge-
ment, and we subsequently withdrew as much of the
agent as possible. In order to prevent renal damage due
to EOI-induced hemolysis, 4000 units of haptoglobin
(Yoshitomi, Osaka, Japan) was intravenously adminis-
tered before the EOI infusion. To evaluate the therapeu-
tic efficacy of gastric varices, we performed contrast-
enhanced CT 5 days after B-RTO. As a general rule, if
the gastric varices were not thrombosed, B-RTO was
repeated 7 days after the first procedure. Further, if the
varices were not thrombosed even after the second or
third procedure, a repeat B-RTO procedure was sched-
uled after 2 or 3 months.
Follow-up examination
Follow-up CT and endoscopy were performed every 3-6
months. Depending on the patient’s condition, the
attending physician decided the follow-up interval. The
recurrence of gastric varices was evaluated by perform-
ing follow-up endoscopy or contrast-enhanced CT. Fol-
low-up evaluation of the esophageal varices was
performed via endoscopy. When the follow-up endo-
scopy revealed newly developed esophageal varices, red
spots on preexisting esophageal varices, or esophageal
variceal bleeding, the esophageal varices were regarded
as having worsened.
Definitions and Statistical Analysis
When the sclerosing agent was successfully injected and
complete thrombosis of the varices, as observed on a
contrast-enhanced CT scan after the first or subsequent
B-RTO procedure, was achieved, B-RTO was considered
successful. B-RTO failure was classified as either techni-
cal failure or thrombosis failure. Technical failure was
defined as the inability of performing the B-RTO proce-
dure. Thrombosis failure was defined as technically suc-
cessful completion of the B-RTO procedure without
thrombosis of gastric varices on the follow-up contrast-
enhanced CT scan. The rates of patient survival and
recurrence of the gastric and esophageal varices were
calculated using the Kaplan-Meier method.
Results
Outcome of B-RTO
In 37 of the 47 patients (79%), B-RTO was technically
successful and complete thrombosis of the varices was
observed on the contrast-enhanced CT scans. Of these
37 patients, B-RTO was performed once in 26 patients
(70%), twice in 6 patients (16%), thrice in 2 patients
(6%), and 4 times in 3 patients (8%). However, this tech-
nique was not successful in the other 10 patients. In 6
of these 10 patients, B-RTO could not be performed
(technical failure) for the following reasons: (1) the gas-
trorenal shunt could not be occluded with the balloon
catheter because the shunt was extremely large and
because of rapid blood flow in the area (2 cases); (2)
catheterization was difficult owing to the presence of
fine and tortuous gastrocaval or gastrorenal shunts (2
cases); and (3) the gastric varices could not be visualized
owing to the presence of many retroperitoneal veins (2
cases). Thrombosis failure was observed in 4 patients. In
this group, B-RTO was performed once in 2 patients,
thrice in 1 patient, and 4 times in 1 patient, but throm-
bosis of the varices could not be achieved. Among the
10 patients in whom this procedure failed, 3 underwent
endoscopic injection therapy instead of B-RTO. The
other patients did not provide their consent for further
treatment.
Complications
Complications occurred during the procedures in the
case of 4 patients. In 1 patient, iatrogenic injury to the
gastrorenal shunt occurred during catheterization. The
patient’s vital signs remained normal, but no additional
angiographic analyses or intervention was carried out at
that time. After 2 months, B-RTO was attempted for
the second time, and it was successful. In another
patient, a microcoil (diameter, 3 mm) that was used for
embolization of the inferior phrenic vein migrated to
the distal region of the right pulmonary artery. Since the
coil was small and since its potential adverse effects
were considered to be minimal, we did not attempt to
retrieve it. In the other 2 patients, the sclerosing agent
entered systemic circulation within 5 minutes owing to
dislodgement of the balloon catheter. One of these
patients experienced chest discomfort, and his pulse
oxygen saturation (SpO2) levels transiently decreased.
Hence, no additional intervention was performed at that
time, but B-RTO was repeated at a later date.
Survival
Among the 37 patients who successfully underwent B-
RTO, 3 were lost to follow-up. Thus, 34 patients were
followed up and their cases reviewed. The median fol-
low-up period was 1147 days (range, 15-3375 days), dur-
ing which time 5 patients died. Of these, 2 died soon
after the procedure: 1 patient who underwent endo-
scopic injection sclerotherapy for esophageal varices
after B-RTO died after 15 days of sepsis caused by
severe diabetes mellitus; the other died after 71 days
because of rupture of esophageal varices. Of the other 3
patients who died, 2 died from hepatocellular carcinoma
(784 days and 1326 days after B-RTO) and 1 died of
hepatic failure (1345 days after B-RTO). The overall
cumulative survival rate at 1, 3, and 5 years after B-RTO
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was 92%, 90%, and 73%, respectively, as determined by
the Kaplan-Meier method (Fig. 2).
Recurrence of gastric varices and gastrorenal shunt
patency
As mentioned above, among the 37 patients who suc-
cessfully underwent B-RTO, 3 were lost to follow-up
and 2 died soon after the procedure. The remaining 32
patients were followed up for detecting the recurrence
of gastric varices and progression of esophageal varices.
During the median follow-up period of 746 days (range,
134-3136 days), the gastric varices recurred in 2 patients
(after 13 months in one and after 28 months in the
other). The overall cumulative relapse-free rate of gastric
varices was 90% at 3 and 5 years after the first B-RTO
(Fig. 3). We also analyzed perigastric gastrorenal shunt
thrombosis as well as gastric variceal thrombosis on
contrast-enhanced CT scans obtained after the B-RTO
procedure. In the 32 patients who were followed up,
gastrorenal shunt thrombosis, as well as gastric variceal
thrombosis, was observed in 25 patients, and gastric
Figure 1 Balloon-occluded retrograde transvenous obliteration (B-RTO) performed on a 47-year-old woman with hepatitis C virus-
related liver cirrhosis. A. A balloon catheter was inserted into the gastrorenal shunt. The gastric varices could not be clearly visualized on the
venogram because the contrast medium had leaked into the retroperitoneal collateral veins (arrow). B. The retroperitoneal collateral veins were
catheterized using a microcatheter and embolized using metallic coils. The gastric varices (arrow) could be clearly visualized on a venogram
obtained after embolization of the retroperitoneal veins. C. A contrast-enhanced CT scan obtained before the B-RTO procedure showed gastric
varices and gastrorenal shunts. D. A contrast-enhanced CT scan obtained 5 days after the first B-RTO procedure showed complete thrombosis of
the gastric varices (arrowhead).
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variceal thrombosis without gastrorenal shunt thrombo-
sis was observed in 7 patients. Gastric variceal recur-
rence occurred in 2 cases of gastric variceal thrombosis
without gastrorenal shunt thrombosis. These 2 patients
underwent additional B-RTO procedures, and complete
thrombosis of the gastric varices and gastrorenal shunt
were achieved. We also treated 3 patients in whom the
gastric varices recurred after the emergency endoscopic
injection therapy using cyanoacrylate. In these patients,
the gastrorenal shunt remained patent, and the residual
gastric varices appeared opacified during balloon-
occluded retrograde venography; B-RTO was successful
for these patients (Fig. 4). However, in one of these
cases, contrast-enhanced CT revealed a patent gastrore-
nal shunt, and the gastric varices recurred 28 months
after B-RTO (as mentioned above).
Progression of esophageal varices
In contrast, esophageal varices worsened in 14 patients
during the follow-up period (median, 656 days; range,
80-3136 days). The overall cumulative progression-free
rates of esophageal varices at 1, 3, and 5 years were
93%, 47%, and 38%, respectively (Fig. 5). Among these
14 patients, 2 patients had bleeding esophageal varices
and 7 patients were at a risk of bleeding from esopha-
geal varices. They underwent endoscopic injection
sclerotherapy.
Discussion
The risk of bleeding from gastric varices is lower than
that of bleeding from esophageal varices, but rupture of
gastric varices is a serious condition associated with a
mortality rate of 25-55% [1-4]. The risk factors for
hemorrhage from gastric varices are large-sized varices,
the presence of red spots on varices, and a severe
Child’s status [4]. The available treatment options for
gastric varices include shunt surgery, endoscopic injec-
tion sclerotherapy (EIS) with cyanoacrylate or ethanola-
mine oleate, and transjugular intrahepatic portosystemic
shunting (TIPS). Gastric varices frequently develop from
the short and posterior gastric veins; this is in contrast
to esophageal varices, which are known to develop
mainly from the coronary vein [12]. In gastric varices
with a large gastro-renal shunt, a sclerosing agent could
even enter the renal shunt and from there, the inferior
vena cava. Therefore, prophylactic EIS is not recom-
mended for the treatment of gastric varices. B-RTO,
which was introduced in the mid-1990s, has proven to
be an effective method for this purpose. Since then, it
has been used for the treatment of hemorrhagic gastric
varices and for prophylactic treatment in Japan. Ninoi et
al. reported that transcatheter sclerotherapy procedures
such as B-RTO may be more effective than TIPS in con-
trolling gastric variceal bleeding [13]. In our study, the
gastric varices recurred in only 2 patients, and no bleed-
ing was observed. The overall cumulative relapse-free
rate was 90% at 3 and 5 years after B-RTO. However,
worsening of esophageal varices is one problem after B-
RTO in long-term follow up as widely reported in some
articles [8,10,11]. In our study, 44% of patients experi-
enced worsening of their esophageal varices during
median follow-up period of 656 days. Therefore, endo-
scopic examination is extremely important for discover-
ing worsening of esophageal varices after B-RTO.
Although B-RTO is more efficient than other techni-
ques and procedures and provides better long-term
results, it may be difficult to achieve technical success in
cases where the collateral vessels are numerous and
large. Even in cases where the collateral vessels are
occluded, multiple B-RTO procedures are frequently
required to completely obliterate the gastric varices.
Moreover, alternative procedures such as percutaneous
transhepatic sclerotherapy may be necessary in some
cases where B-RTO is unsuccessful [13].
Figure 2 Cumulative survival rate after B-RTO.
Figure 3 Cumulative relapse-free rate of gastric varices after B-
RTO.
Katoh et al. BMC Medical Imaging 2010, 10:2
http://www.biomedcentral.com/1471-2342/10/2
Page 5 of 8
In our study, 32 patients who successfully underwent
B-RTO were followed-up. Contrast-enhanced CT per-
formed after the B-RTO procedure revealed thrombosis
of the gastrorenal shunt as well as gastric varices in the
case of 25 patients, and thrombosis of the gastric varices
with patency of the gastrorenal shunts in the case of 7
patients. The gastric varices recurred in 2 patients who
had patent gastrorenal shunts–at 13 months after B-
RTO in one and at 28 months after B-RTO in the
other. In addition, the varices recurred after endoscopic
injection therapy using cyanoacrylate in the case of 3
patients in whom the gastrorenal shunts remained
patent. The B-RTO procedure is performed to achieve
retrograde obliteration of gastric varices through a
draining vein. Even in cases where the gastric varices
appear thrombosed on contrast-enhanced CT scans, a
small region of the varices and the gastrorenal shunt
may remain patent and induce regrowth of the gastric
Figure 4 B-RTO performed on a 49-year-old man with alcohol-related liver cirrhosis. A CT scan obtained during arterioportography
showed gastric fundal varices. B. Bleeding of the gastric varices occurred before the scheduled B-RTO procedure, and endoscopic injection
sclerotherapy (EIS) using cyanoacrylate was performed as an emergency procedure to control the bleeding. A plain CT scan obtained after EIS
showed that the sclerosing agent was almost uniformly distributed throughout the network of gastric varices (arrow), except in the gastrorenal
shunt. The scheduled B-RTO was cancelled because the bleeding of the gastric varices ceased after the emergency EIS. C. The patient had a
history of repeated gastric variceal bleeding and was referred to our department for a B-RTO procedure 4 years after he had received EIS for the
first time. The venogram revealed a gastrorenal shunt; however, the gastric varices could not be clearly visualized because the contrast medium
had leaked into systemic circulation. D. A retrograde venogram obtained after coil embolization of the inferior phrenic vein (arrow) clearly
showed the recurrence of gastric varices (arrowhead). The gastric varices were completely thrombosed after the first B-RTO procedure, as
determined by CT during follow-up.
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varices (Fig. 6). Several investigators have reported that
the use of a microcatheter during B-RTO enables selec-
tive obliteration of gastric varices while maintaining the
patency of the gastrorenal shunt [14,15]. However, as
observed in our study, a patent gastrorenal shunt may
cause recurrence of gastric varices. Therefore, oblitera-
tion of the gastrorenal shunt as well as the gastric
varices is essential.
Recently, a group of Korean investigators also reported
the use of B-RTO for the treatment of gastric varices
[16]. They reported that B-RTO is an effective treatment
for the obliteration of gastric varices. However, postpro-
cedural liver failure resulted in the death or the
discharge as hopeless within 2 months of 6 patients, and
procedure-related death occurred in the case of 2
patients who were classified as C or late B (scores of 8
or 9) according to the Child-Pugh classification system.
Therefore, they concluded that the use of this procedure
in severely compromised patients should be considered
carefully. In contrast to their results, we did not experi-
ence procedure-related liver failure; this was probably
because the majority of our patients had early-stage liver
disease. B-RTO is highly efficacious for the treatment of
gastric varices; therefore, in Japan, it is often used as a
prophylactic treatment technique before the rupture of
gastric varices. Some authors have insisted that prophy-
lactic treatment results in good survival rates [17]. B-
RTO is widely accepted in Japan, but not in other parts
of the world. In particular, there is no mention of B-
RTO in the AASLD (American Association for the
Study of Liver Diseases) guidelines [18]. For this therapy
to be accepted universally, randomized controlled trials
are required. In addition, further studies are required to
evaluate the indications of this therapy in patients with
poor liver function and the necessity of prophylactic
treatment.
Conclusion
In summary, B-RTO is an effective method for the treat-
ment of patients with gastric varices. Moreover, oblitera-
tion of the gastrorenal shunt as well as the varices
appears to be particularly important for preventing the
recurrence of gastric varices in this procedure.
Figure 5 Cumulative progression-free rate of esophageal
varices after B-RTO.
Figure 6 Illustration of gastric varices after B-RTO. A. The gastric varices and gastrorenal shunt are thrombosed. B. The gastric varices are
thrombosed, but a small region of the varices remains and the gastrorenal shunt are patent. These conditions may induce gradual regrowth of
the varices.
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